Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar bought 5,000 shares of the firm's stock in a transaction that occurred on Friday, October 30th. The shares were acquired at an average cost of $3.17 per share, for a total transaction of $15,850.00. Following the completion of the acquisition, the chief executive officer directly owned 685,000 shares in the company, valued at $2,171,450. The trade was a 0.74% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Amit Kumar also recently made the following trade(s):
- On Thursday, October 22nd, Amit Kumar acquired 8,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $2.72 per share, with a total value of $21,760.00.
- On Thursday, September 24th, Amit Kumar purchased 7,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $2.78 per share, for a total transaction of $19,460.00.
- On Thursday, September 10th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $2.75 per share, for a total transaction of $8,250.00.
- On Thursday, September 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $2.76 per share, with a total value of $13,800.00.
Anixa Biosciences Stock Performance
Shares of NASDAQ:ANIX traded down $0.07 during midday trading on Monday, reaching $3.05. The company's stock had a trading volume of 51,734 shares, compared to its average volume of 208,651. The firm has a market capitalization of $106.02 million, a price-to-earnings ratio of -9.53 and a beta of 0.47. The firm has a 50 day moving average price of $2.97 and a two-hundred day moving average price of $2.97. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). As a group, research analysts anticipate that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of ANIX. BlackRock Inc. purchased a new position in shares of Anixa Biosciences during the 2nd quarter valued at about $559,000. GSA Capital Partners LLP purchased a new position in shares of Anixa Biosciences in the second quarter valued at about $329,000. CoreCap Advisors LLC boosted its stake in shares of Anixa Biosciences by 19.2% in the third quarter. CoreCap Advisors LLC now owns 62,020 shares of the company's stock worth $182,000 after acquiring an additional 10,000 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Anixa Biosciences by 13.6% in the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company's stock worth $158,000 after acquiring an additional 7,300 shares during the period. Finally, Kestra Advisory Services LLC lifted its holdings in Anixa Biosciences by 96.2% in the 1st quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company's stock worth $132,000 after purchasing an additional 25,000 shares in the last quarter. Institutional investors own 29.13% of the company's stock.
Analyst Ratings Changes
A number of research firms have recently weighed in on ANIX. Weiss Ratings raised Anixa Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 17th. Wall Street Zen cut Anixa Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright reduced their price target on Anixa Biosciences from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, September 22nd. Citigroup reissued a "buy" rating on shares of Anixa Biosciences in a research report on Tuesday, October 6th. Finally, Zacks Research cut shares of Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $8.00.
Read Our Latest Stock Analysis on Anixa Biosciences
About Anixa Biosciences
(
Get Free Report)
Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company's programs are designed to use the immune system to identify and attack disease-associated targets.
Anixa's oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Anixa Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anixa Biosciences wasn't on the list.
While Anixa Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.